Company intelligence / Profile preview

Fujifilm

Kanagawa Prefecture, Japanfujifilm.com ↗

Ownership: Public · 4901
Development stage: Other

Overview

Fujifilm has several products in clinical development, including FF-10502-01 (Phase 2 for Cholangiocarcinoma), FF-10832 (Phase 1/2 for various cancers), and FF-10850 (Phase 1 for Merkel cell carcinoma). They received approval for Favipiravir in Japan for SFTS treatment in June 2024[6].

Therapeutic areas: Infectious DiseasesOncology
Modalities: Liposomal drug delivery systemssmall moleculesrecombinant proteinsviral vaccinesgene therapies
Industry: Biotech

Drug pipeline

8 assets

favipiravir

7 more assets in the full pipeline.

Request access →

Partnerships

Xerox Limited (formerly Rank Xerox Limited)

Beyond the preview

Go deeper on Fujifilm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fujifilm.

Explore the full profile